Skip to main content
Top
Published in:

03-01-2024 | Breast Cancer | Review

Glucocorticoid receptor: a harmonizer of cellular plasticity in breast cancer—directs the road towards therapy resistance, metastatic progression and recurrence

Authors: Debanjan Thakur, Debomita Sengupta, Elizabeth Mahapatra, Salini Das, Ruma Sarkar, Sutapa Mukherjee

Published in: Cancer and Metastasis Reviews | Issue 1/2024

Login to get access

Abstract

Recent therapeutic advances have significantly uplifted the quality of life in breast cancer patients, yet several impediments block the road to disease-free survival. This involves unresponsiveness towards administered therapy, epithelial to mesenchymal transition, and metastatic progression with the eventual appearance of recurrent disease. Attainment of such characteristics is a huge adaptive challenge to which tumour cells respond by acquiring diverse phenotypically plastic states. Several signalling networks and mediators are involved in such a process. Glucocorticoid receptor being a mediator of stress response imparts prognostic significance in the context of breast carcinoma. Involvement of the glucocorticoid receptor in the signalling cascade of breast cancer phenotypic plasticity needs further elucidation. This review attempted to shed light on the inter-regulatory interactions of the glucocorticoid receptor with the mediators of the plasticity program in breast cancer; which may provide a hint for strategizing therapeutics against the glucocorticoid/glucocorticoid receptor axis so as to modulate phenotypic plasticity in breast carcinoma.
Literature
1.
2.
go back to reference Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a Cancer Journal for Clinicians, 71(3), 209–249. https://doi.org/10.3322/caac.21660CrossRefPubMed Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a Cancer Journal for Clinicians, 71(3), 209–249. https://​doi.​org/​10.​3322/​caac.​21660CrossRefPubMed
13.
19.
go back to reference West, D. C., Pan, D., Tonsing-Carter, E. Y., Hernandez, K. M., Pierce, C. F., Styke, S. C., Bowie, K. R., Garcia, T. I., Kocherginsky, M., & Conzen, S. D. (2016). GR and ER Coactivation alters the expression of differentiation genes and associates with improved ER+ breast cancer outcome. Molecular cancer research: MCR, 14(8), 707–719. https://doi.org/10.1158/1541-7786.MCR-15-0433CrossRefPubMed West, D. C., Pan, D., Tonsing-Carter, E. Y., Hernandez, K. M., Pierce, C. F., Styke, S. C., Bowie, K. R., Garcia, T. I., Kocherginsky, M., & Conzen, S. D. (2016). GR and ER Coactivation alters the expression of differentiation genes and associates with improved ER+ breast cancer outcome. Molecular cancer research: MCR, 14(8), 707–719. https://​doi.​org/​10.​1158/​1541-7786.​MCR-15-0433CrossRefPubMed
20.
go back to reference Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., Carey, L., Corneliussen-James, D., Curigliano, G., Dieras, V., El Saghir, N., Eniu, A., Fallowfield, L., Fenech, D., Francis, P., et al. (2017). 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Annals of Oncology: Official Journal of the European Society for Medical Oncology, 28(1), 16–33. https://doi.org/10.1093/annonc/mdw544CrossRefPubMed Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., Carey, L., Corneliussen-James, D., Curigliano, G., Dieras, V., El Saghir, N., Eniu, A., Fallowfield, L., Fenech, D., Francis, P., et al. (2017). 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Annals of Oncology: Official Journal of the European Society for Medical Oncology, 28(1), 16–33. https://​doi.​org/​10.​1093/​annonc/​mdw544CrossRefPubMed
22.
29.
go back to reference Dirkse, A., Golebiewska, A., Buder, T., Nazarov, P. V., Muller, A., Poovathingal, S., Brons, N. H. C., Leite, S., Sauvageot, N., Sarkisjan, D., Seyfrid, M., Fritah, S., Stieber, D., Michelucci, A., Hertel, F., Herold-Mende, C., Azuaje, F., Skupin, A., Bjerkvig, R., et al. (2019). Stem cell-associated heterogeneity in glioblastoma results from intrinsic tumor plasticity shaped by the microenvironment. Nature Communications, 10(1), 1787. https://doi.org/10.1038/s41467-019-09853-zCrossRefPubMedPubMedCentral Dirkse, A., Golebiewska, A., Buder, T., Nazarov, P. V., Muller, A., Poovathingal, S., Brons, N. H. C., Leite, S., Sauvageot, N., Sarkisjan, D., Seyfrid, M., Fritah, S., Stieber, D., Michelucci, A., Hertel, F., Herold-Mende, C., Azuaje, F., Skupin, A., Bjerkvig, R., et al. (2019). Stem cell-associated heterogeneity in glioblastoma results from intrinsic tumor plasticity shaped by the microenvironment. Nature Communications, 10(1), 1787. https://​doi.​org/​10.​1038/​s41467-019-09853-zCrossRefPubMedPubMedCentral
31.
go back to reference Prekovic, S., Schuurman, K., Mayayo-Peralta, I., Manjón, A. G., Buijs, M., Yavuz, S., Wellenstein, M. D., Barrera, A., Monkhorst, K., Huber, A., Morris, B., Lieftink, C., Chalkiadakis, T., Alkan, F., Silva, J., Győrffy, B., Hoekman, L., van den Broek, B., Teunissen, H., et al. (2021). Glucocorticoid receptor triggers a reversible drug-tolerant dormancy state with acquired therapeutic vulnerabilities in lung cancer. Nature Communications, 12(1), 4360. https://doi.org/10.1038/s41467-021-24537-3CrossRefPubMedPubMedCentral Prekovic, S., Schuurman, K., Mayayo-Peralta, I., Manjón, A. G., Buijs, M., Yavuz, S., Wellenstein, M. D., Barrera, A., Monkhorst, K., Huber, A., Morris, B., Lieftink, C., Chalkiadakis, T., Alkan, F., Silva, J., Győrffy, B., Hoekman, L., van den Broek, B., Teunissen, H., et al. (2021). Glucocorticoid receptor triggers a reversible drug-tolerant dormancy state with acquired therapeutic vulnerabilities in lung cancer. Nature Communications, 12(1), 4360. https://​doi.​org/​10.​1038/​s41467-021-24537-3CrossRefPubMedPubMedCentral
43.
go back to reference Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C., Elias, A. D., Giordano, S. H., Goetz, M. P., Goldstein, L. J., Isakoff, S. J., Krishnamurthy, J., Lyons, J., Marcom, P. K., Matro, J., Mayer, I. A., et al. (2020). Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 18(4), 452–478. https://doi.org/10.6004/jnccn.2020.0016CrossRefPubMed Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C., Elias, A. D., Giordano, S. H., Goetz, M. P., Goldstein, L. J., Isakoff, S. J., Krishnamurthy, J., Lyons, J., Marcom, P. K., Matro, J., Mayer, I. A., et al. (2020). Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 18(4), 452–478. https://​doi.​org/​10.​6004/​jnccn.​2020.​0016CrossRefPubMed
44.
go back to reference Khatcheressian, J. L., Hurley, P., Bantug, E., Esserman, L. J., Grunfeld, E., Halberg, F., Hantel, A., Henry, N. L., Muss, H. B., Smith, T. J., Vogel, V. G., Wolff, A. C., Somerfield, M. R., Davidson, N. E., & American Society of Clinical Oncology. (2013). Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 31(7), 961–965. https://doi.org/10.1200/JCO.2012.45.9859CrossRefPubMed Khatcheressian, J. L., Hurley, P., Bantug, E., Esserman, L. J., Grunfeld, E., Halberg, F., Hantel, A., Henry, N. L., Muss, H. B., Smith, T. J., Vogel, V. G., Wolff, A. C., Somerfield, M. R., Davidson, N. E., & American Society of Clinical Oncology. (2013). Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 31(7), 961–965. https://​doi.​org/​10.​1200/​JCO.​2012.​45.​9859CrossRefPubMed
54.
go back to reference Hata, S., Shimada, H., Sato, N., Koshiishi, M., Ise, K., Ogata, T., Yamashita, S., Ito, A., Sasano, H., & Nakamura, Y. (2022). Expression and clinicopathological significance of glucocorticoid receptor, SGK1, and NDRG1 in hormone-naïve prostate carcinoma. Medical Molecular Morphology, 55(4), 283–291. https://doi.org/10.1007/s00795-022-00332-xCrossRefPubMed Hata, S., Shimada, H., Sato, N., Koshiishi, M., Ise, K., Ogata, T., Yamashita, S., Ito, A., Sasano, H., & Nakamura, Y. (2022). Expression and clinicopathological significance of glucocorticoid receptor, SGK1, and NDRG1 in hormone-naïve prostate carcinoma. Medical Molecular Morphology, 55(4), 283–291. https://​doi.​org/​10.​1007/​s00795-022-00332-xCrossRefPubMed
57.
go back to reference Pastushenko, I., Brisebarre, A., Sifrim, A., Fioramonti, M., Revenco, T., Boumahdi, S., Van Keymeulen, A., Brown, D., Moers, V., Lemaire, S., De Clercq, S., Minguijón, E., Balsat, C., Sokolow, Y., Dubois, C., De Cock, F., Scozzaro, S., Sopena, F., Lanas, A., et al. (2018). Identification of the tumour transition states occurring during EMT. Nature, 556(7702), 463–468. https://doi.org/10.1038/s41586-018-0040-3CrossRefPubMed Pastushenko, I., Brisebarre, A., Sifrim, A., Fioramonti, M., Revenco, T., Boumahdi, S., Van Keymeulen, A., Brown, D., Moers, V., Lemaire, S., De Clercq, S., Minguijón, E., Balsat, C., Sokolow, Y., Dubois, C., De Cock, F., Scozzaro, S., Sopena, F., Lanas, A., et al. (2018). Identification of the tumour transition states occurring during EMT. Nature, 556(7702), 463–468. https://​doi.​org/​10.​1038/​s41586-018-0040-3CrossRefPubMed
62.
go back to reference Shi, R. Z., He, Y. F., Wen, J., Niu, Y. N., Gao, Y., Liu, L. H., Zhang, X. P., Wang, Y., Zhang, X. L., Zhang, H. F., Chen, M., & Hu, X. L. (2021). Epithelial cell adhesion molecule promotes breast cancer resistance protein-mediated multidrug resistance in breast cancer by inducing partial epithelial-mesenchymal transition. Cell Biology International, 45(8), 1644–1653. https://doi.org/10.1002/cbin.11598CrossRefPubMed Shi, R. Z., He, Y. F., Wen, J., Niu, Y. N., Gao, Y., Liu, L. H., Zhang, X. P., Wang, Y., Zhang, X. L., Zhang, H. F., Chen, M., & Hu, X. L. (2021). Epithelial cell adhesion molecule promotes breast cancer resistance protein-mediated multidrug resistance in breast cancer by inducing partial epithelial-mesenchymal transition. Cell Biology International, 45(8), 1644–1653. https://​doi.​org/​10.​1002/​cbin.​11598CrossRefPubMed
64.
go back to reference Xiao, L., Zhang, C., Li, X., Jia, C., Chen, L., Yuan, Y., Gao, Q., Lu, Z., Feng, Y., Zhao, R., Zhao, X., Cheng, S., Shu, Z., Xu, J., Duan, W., Nie, G., & Hou, Y. (2021). LEF1 enhances the progression of colonic adenocarcinoma via remodeling the cell motility associated structures. International Journal of Molecular Sciences, 22(19), 10870. https://doi.org/10.3390/ijms221910870CrossRefPubMedPubMedCentral Xiao, L., Zhang, C., Li, X., Jia, C., Chen, L., Yuan, Y., Gao, Q., Lu, Z., Feng, Y., Zhao, R., Zhao, X., Cheng, S., Shu, Z., Xu, J., Duan, W., Nie, G., & Hou, Y. (2021). LEF1 enhances the progression of colonic adenocarcinoma via remodeling the cell motility associated structures. International Journal of Molecular Sciences, 22(19), 10870. https://​doi.​org/​10.​3390/​ijms221910870CrossRefPubMedPubMedCentral
65.
go back to reference Blazquez, R., Rietkötter, E., Wenske, B., Wlochowitz, D., Sparrer, D., Vollmer, E., Müller, G., Seegerer, J., Sun, X., Dettmer, K., Barrantes-Freer, A., Stange, L., Utpatel, K., Bleckmann, A., Treiber, H., Bohnenberger, H., Lenz, C., Schulz, M., Reimelt, C., et al. (2020). LEF1 supports metastatic brain colonization by regulating glutathione metabolism and increasing ROS resistance in breast cancer. International Journal of Cancer, 146(11), 3170–3183. https://doi.org/10.1002/ijc.32742CrossRefPubMed Blazquez, R., Rietkötter, E., Wenske, B., Wlochowitz, D., Sparrer, D., Vollmer, E., Müller, G., Seegerer, J., Sun, X., Dettmer, K., Barrantes-Freer, A., Stange, L., Utpatel, K., Bleckmann, A., Treiber, H., Bohnenberger, H., Lenz, C., Schulz, M., Reimelt, C., et al. (2020). LEF1 supports metastatic brain colonization by regulating glutathione metabolism and increasing ROS resistance in breast cancer. International Journal of Cancer, 146(11), 3170–3183. https://​doi.​org/​10.​1002/​ijc.​32742CrossRefPubMed
70.
go back to reference Li, S., Lu, J., Chen, Y., Xiong, N., Li, L., Zhang, J., Yang, H., Wu, C., Zeng, H., & Liu, Y. (2017). MCP-1-induced ERK/GSK-3β/Snail signaling facilitates the epithelial-mesenchymal transition and promotes the migration of MCF-7 human breast carcinoma cells. Cellular & Molecular Immunology, 14(7), 621–630. https://doi.org/10.1038/cmi.2015.106CrossRef Li, S., Lu, J., Chen, Y., Xiong, N., Li, L., Zhang, J., Yang, H., Wu, C., Zeng, H., & Liu, Y. (2017). MCP-1-induced ERK/GSK-3β/Snail signaling facilitates the epithelial-mesenchymal transition and promotes the migration of MCF-7 human breast carcinoma cells. Cellular & Molecular Immunology, 14(7), 621–630. https://​doi.​org/​10.​1038/​cmi.​2015.​106CrossRef
76.
82.
go back to reference Xu, C., Yan, T., & Yang, J. (2019). OVOL1 inhibits oral squamous cell carcinoma growth and metastasis by suppressing zinc finger E-box binding homeobox 1. International Journal of Clinical and Experimental Pathology, 12(7), 2801–2808.PubMedPubMedCentral Xu, C., Yan, T., & Yang, J. (2019). OVOL1 inhibits oral squamous cell carcinoma growth and metastasis by suppressing zinc finger E-box binding homeobox 1. International Journal of Clinical and Experimental Pathology, 12(7), 2801–2808.PubMedPubMedCentral
88.
go back to reference Reese, R. M., Helzer, K. T., Allen, K. O., Zheng, C., Solodin, N., & Alarid, E. T. (2022). GRHL2 enhances phosphorylated estrogen receptor (ER) chromatin binding and regulates ER-mediated transcriptional activation and repression. Molecular and Cellular Biology, 42(10), e0019122. https://doi.org/10.1128/mcb.00191-22CrossRefPubMed Reese, R. M., Helzer, K. T., Allen, K. O., Zheng, C., Solodin, N., & Alarid, E. T. (2022). GRHL2 enhances phosphorylated estrogen receptor (ER) chromatin binding and regulates ER-mediated transcriptional activation and repression. Molecular and Cellular Biology, 42(10), e0019122. https://​doi.​org/​10.​1128/​mcb.​00191-22CrossRefPubMed
92.
go back to reference Liu, H., Song, Y., Qiu, H., Liu, Y., Luo, K., Yi, Y., Jiang, G., Lu, M., Zhang, Z., Yin, J., Zeng, S., Chen, X., Deng, M., Jia, X., Gu, Y., Chen, D., Zheng, G., & He, Z. (2020). Downregulation of FOXO3a by DNMT1 promotes breast cancer stem cell properties and tumorigenesis. Cell Death and Differentiation, 27(3), 966–983. https://doi.org/10.1038/s41418-019-0389-3CrossRefPubMed Liu, H., Song, Y., Qiu, H., Liu, Y., Luo, K., Yi, Y., Jiang, G., Lu, M., Zhang, Z., Yin, J., Zeng, S., Chen, X., Deng, M., Jia, X., Gu, Y., Chen, D., Zheng, G., & He, Z. (2020). Downregulation of FOXO3a by DNMT1 promotes breast cancer stem cell properties and tumorigenesis. Cell Death and Differentiation, 27(3), 966–983. https://​doi.​org/​10.​1038/​s41418-019-0389-3CrossRefPubMed
98.
114.
go back to reference Dong, J., Lv, Z., Chen, Q., Wang, X., & Li, F. (2018). PRRX1 drives tamoxifen therapy resistance through induction of epithelial-mesenchymal transition in MCF-7 breast cancer cells. International Journal of Clinical and Experimental Pathology, 11(5), 2629–2635.PubMedPubMedCentral Dong, J., Lv, Z., Chen, Q., Wang, X., & Li, F. (2018). PRRX1 drives tamoxifen therapy resistance through induction of epithelial-mesenchymal transition in MCF-7 breast cancer cells. International Journal of Clinical and Experimental Pathology, 11(5), 2629–2635.PubMedPubMedCentral
120.
go back to reference Regan Anderson, T. M., Ma, S. H., Raj, G. V., Cidlowski, J. A., Helle, T. M., Knutson, T. P., Krutilina, R. I., Seagroves, T. N., & Lange, C. A. (2016). Breast tumor kinase (Brk/PTK6) is induced by HIF, glucocorticoid receptor, and PELP1-mediated stress signaling in triple-negative breast cancer. Cancer Research, 76(6), 1653–1663. https://doi.org/10.1158/0008-5472.CAN-15-2510CrossRefPubMed Regan Anderson, T. M., Ma, S. H., Raj, G. V., Cidlowski, J. A., Helle, T. M., Knutson, T. P., Krutilina, R. I., Seagroves, T. N., & Lange, C. A. (2016). Breast tumor kinase (Brk/PTK6) is induced by HIF, glucocorticoid receptor, and PELP1-mediated stress signaling in triple-negative breast cancer. Cancer Research, 76(6), 1653–1663. https://​doi.​org/​10.​1158/​0008-5472.​CAN-15-2510CrossRefPubMed
123.
go back to reference Bi, X., Lou, P., Song, Y., Sheng, X., Liu, R., Deng, M., Yang, X., Li, G., Yuan, S., Zhang, H., Jiao, B., Zhang, B., Xue, L., Liu, Z., Plikus, M. V., Ren, F., Gao, S., Zhao, L., & Yu, Z. (2021). Msi1 promotes breast cancer metastasis by regulating invadopodia-mediated extracellular matrix degradation via the Timp3-Mmp9 pathway. Oncogene, 40(29), 4832–4845. https://doi.org/10.1038/s41388-021-01873-8CrossRefPubMed Bi, X., Lou, P., Song, Y., Sheng, X., Liu, R., Deng, M., Yang, X., Li, G., Yuan, S., Zhang, H., Jiao, B., Zhang, B., Xue, L., Liu, Z., Plikus, M. V., Ren, F., Gao, S., Zhao, L., & Yu, Z. (2021). Msi1 promotes breast cancer metastasis by regulating invadopodia-mediated extracellular matrix degradation via the Timp3-Mmp9 pathway. Oncogene, 40(29), 4832–4845. https://​doi.​org/​10.​1038/​s41388-021-01873-8CrossRefPubMed
129.
go back to reference Georgopoulou, D., Callari, M., Rueda, O. M., Shea, A., Martin, A., Giovannetti, A., Qosaj, F., Dariush, A., Chin, S. F., Carnevalli, L. S., Provenzano, E., Greenwood, W., Lerda, G., Esmaeilishirazifard, E., O’Reilly, M., Serra, V., Bressan, D., Consortium, I. M. A. X. T., Mills, G. B., et al. (2021). Landscapes of cellular phenotypic diversity in breast cancer xenografts and their impact on drug response. Nature Communications, 12(1), 1998. https://doi.org/10.1038/s41467-021-22303-zCrossRefPubMedPubMedCentral Georgopoulou, D., Callari, M., Rueda, O. M., Shea, A., Martin, A., Giovannetti, A., Qosaj, F., Dariush, A., Chin, S. F., Carnevalli, L. S., Provenzano, E., Greenwood, W., Lerda, G., Esmaeilishirazifard, E., O’Reilly, M., Serra, V., Bressan, D., Consortium, I. M. A. X. T., Mills, G. B., et al. (2021). Landscapes of cellular phenotypic diversity in breast cancer xenografts and their impact on drug response. Nature Communications, 12(1), 1998. https://​doi.​org/​10.​1038/​s41467-021-22303-zCrossRefPubMedPubMedCentral
138.
140.
147.
go back to reference Alam, M. M., Okazaki, K., Nguyen, L. T. T., Ota, N., Kitamura, H., Murakami, S., Shima, H., Igarashi, K., Sekine, H., & Motohashi, H. (2017). Glucocorticoid receptor signaling represses the antioxidant response by inhibiting histone acetylation mediated by the transcriptional activator NRF2. The Journal of Biological Chemistry, 292(18), 7519–7530. https://doi.org/10.1074/jbc.M116.773960CrossRefPubMedPubMedCentral Alam, M. M., Okazaki, K., Nguyen, L. T. T., Ota, N., Kitamura, H., Murakami, S., Shima, H., Igarashi, K., Sekine, H., & Motohashi, H. (2017). Glucocorticoid receptor signaling represses the antioxidant response by inhibiting histone acetylation mediated by the transcriptional activator NRF2. The Journal of Biological Chemistry, 292(18), 7519–7530. https://​doi.​org/​10.​1074/​jbc.​M116.​773960CrossRefPubMedPubMedCentral
151.
go back to reference Hollestelle, A., Peeters, J. K., Smid, M., Timmermans, M., Verhoog, L. C., Westenend, P. J., Heine, A. A., Chan, A., Sieuwerts, A. M., Wiemer, E. A., Klijn, J. G., van der Spek, P. J., Foekens, J. A., Schutte, M., den Bakker, M. A., & Martens, J. W. M. (2013). Loss of E-cadherin is not a necessity for epithelial to mesenchymal transition in human breast cancer. Breast Cancer Research and Treatment, 138(1), 47–57. https://doi.org/10.1007/s10549-013-2415-3CrossRefPubMed Hollestelle, A., Peeters, J. K., Smid, M., Timmermans, M., Verhoog, L. C., Westenend, P. J., Heine, A. A., Chan, A., Sieuwerts, A. M., Wiemer, E. A., Klijn, J. G., van der Spek, P. J., Foekens, J. A., Schutte, M., den Bakker, M. A., & Martens, J. W. M. (2013). Loss of E-cadherin is not a necessity for epithelial to mesenchymal transition in human breast cancer. Breast Cancer Research and Treatment, 138(1), 47–57. https://​doi.​org/​10.​1007/​s10549-013-2415-3CrossRefPubMed
153.
go back to reference Kröger, C., Afeyan, A., Mraz, J., Eaton, E. N., Reinhardt, F., Khodor, Y. L., Thiru, P., Bierie, B., Ye, X., Burge, C. B., & Weinberg, R. A. (2019). Acquisition of a hybrid E/M state is essential for tumorigenicity of basal breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 116(15), 7353–7362. https://doi.org/10.1073/pnas.1812876116CrossRefPubMedPubMedCentral Kröger, C., Afeyan, A., Mraz, J., Eaton, E. N., Reinhardt, F., Khodor, Y. L., Thiru, P., Bierie, B., Ye, X., Burge, C. B., & Weinberg, R. A. (2019). Acquisition of a hybrid E/M state is essential for tumorigenicity of basal breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 116(15), 7353–7362. https://​doi.​org/​10.​1073/​pnas.​1812876116CrossRefPubMedPubMedCentral
157.
159.
go back to reference Cazet, A. S., Hui, M. N., Elsworth, B. L., Wu, S. Z., Roden, D., Chan, C. L., Skhinas, J. N., Collot, R., Yang, J., Harvey, K., Johan, M. Z., Cooper, C., Nair, R., Herrmann, D., McFarland, A., Deng, N., Ruiz-Borrego, M., Rojo, F., Trigo, J. M., et al. (2018). Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer. Nature Communications, 9(1), 2897. https://doi.org/10.1038/s41467-018-05220-6CrossRefPubMedPubMedCentral Cazet, A. S., Hui, M. N., Elsworth, B. L., Wu, S. Z., Roden, D., Chan, C. L., Skhinas, J. N., Collot, R., Yang, J., Harvey, K., Johan, M. Z., Cooper, C., Nair, R., Herrmann, D., McFarland, A., Deng, N., Ruiz-Borrego, M., Rojo, F., Trigo, J. M., et al. (2018). Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer. Nature Communications, 9(1), 2897. https://​doi.​org/​10.​1038/​s41467-018-05220-6CrossRefPubMedPubMedCentral
160.
go back to reference Zubeldia-Plazaola, A., Recalde-Percaz, L., Moragas, N., Alcaraz, M., Chen, X., Mancino, M., Fernández-Nogueira, P., Prats de Puig, M., Guzman, F., Noguera-Castells, A., López-Plana, A., Enreig, E., Carbó, N., Almendro, V., Gascón, P., Bragado, P., & Fuster, G. (2018). Glucocorticoids promote transition of ductal carcinoma in situ to invasive ductal carcinoma by inducing myoepithelial cell apoptosis. Breast cancer research: BCR, 20(1), 65. https://doi.org/10.1186/s13058-018-0977-zCrossRefPubMedPubMedCentral Zubeldia-Plazaola, A., Recalde-Percaz, L., Moragas, N., Alcaraz, M., Chen, X., Mancino, M., Fernández-Nogueira, P., Prats de Puig, M., Guzman, F., Noguera-Castells, A., López-Plana, A., Enreig, E., Carbó, N., Almendro, V., Gascón, P., Bragado, P., & Fuster, G. (2018). Glucocorticoids promote transition of ductal carcinoma in situ to invasive ductal carcinoma by inducing myoepithelial cell apoptosis. Breast cancer research: BCR, 20(1), 65. https://​doi.​org/​10.​1186/​s13058-018-0977-zCrossRefPubMedPubMedCentral
164.
go back to reference Foldi, J., O’Meara, T., Marczyk, M., Sanft, T., Silber, A., & Pusztai, L. (2019). Defining risk of late recurrence in early-stage estrogen receptor-positive breast cancer: Clinical versus molecular tools. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 37(16), 1365–1369. https://doi.org/10.1200/JCO.18.01933CrossRefPubMed Foldi, J., O’Meara, T., Marczyk, M., Sanft, T., Silber, A., & Pusztai, L. (2019). Defining risk of late recurrence in early-stage estrogen receptor-positive breast cancer: Clinical versus molecular tools. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 37(16), 1365–1369. https://​doi.​org/​10.​1200/​JCO.​18.​01933CrossRefPubMed
172.
go back to reference Johnson, R. W., Finger, E. C., Olcina, M. M., Vilalta, M., Aguilera, T., Miao, Y., Merkel, A. R., Johnson, J. R., Sterling, J. A., Wu, J. Y., & Giaccia, A. J. (2016). Induction of LIFR confers a dormancy phenotype in breast cancer cells disseminated to the bone marrow. Nature Cell Biology, 18(10), 1078–1089. https://doi.org/10.1038/ncb3408CrossRefPubMedPubMedCentral Johnson, R. W., Finger, E. C., Olcina, M. M., Vilalta, M., Aguilera, T., Miao, Y., Merkel, A. R., Johnson, J. R., Sterling, J. A., Wu, J. Y., & Giaccia, A. J. (2016). Induction of LIFR confers a dormancy phenotype in breast cancer cells disseminated to the bone marrow. Nature Cell Biology, 18(10), 1078–1089. https://​doi.​org/​10.​1038/​ncb3408CrossRefPubMedPubMedCentral
185.
186.
go back to reference Serritella, A. V., Shevrin, D., Heath, E. I., Wade, J. L., Martinez, E., Anderson, A., Schonhoft, J., Chu, Y. L., Karrison, T., Stadler, W. M., & Szmulewitz, R. Z. (2022). Phase I/II trial of enzalutamide and mifepristone, a glucocorticoid receptor antagonist, for metastatic castration-resistant prostate cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 28(8), 1549–1559. https://doi.org/10.1158/1078-0432.CCR-21-4049CrossRefPubMed Serritella, A. V., Shevrin, D., Heath, E. I., Wade, J. L., Martinez, E., Anderson, A., Schonhoft, J., Chu, Y. L., Karrison, T., Stadler, W. M., & Szmulewitz, R. Z. (2022). Phase I/II trial of enzalutamide and mifepristone, a glucocorticoid receptor antagonist, for metastatic castration-resistant prostate cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 28(8), 1549–1559. https://​doi.​org/​10.​1158/​1078-0432.​CCR-21-4049CrossRefPubMed
187.
go back to reference Nanda, R., Stringer-Reasor, E. M., Saha, P., Kocherginsky, M., Gibson, J., Libao, B., Hoffman, P. C., Obeid, E., Merkel, D. E., Khramtsova, G., Skor, M., Krausz, T., Cohen, R. N., Ratain, M. J., Fleming, G. F., & Conzen, S. D. (2016). A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancer. SpringerPlus, 5(1), 947. https://doi.org/10.1186/s40064-016-2457-1CrossRefPubMedPubMedCentral Nanda, R., Stringer-Reasor, E. M., Saha, P., Kocherginsky, M., Gibson, J., Libao, B., Hoffman, P. C., Obeid, E., Merkel, D. E., Khramtsova, G., Skor, M., Krausz, T., Cohen, R. N., Ratain, M. J., Fleming, G. F., & Conzen, S. D. (2016). A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancer. SpringerPlus, 5(1), 947. https://​doi.​org/​10.​1186/​s40064-016-2457-1CrossRefPubMedPubMedCentral
189.
go back to reference Doheny, D., Manore, S., Sirkisoon, S. R., Zhu, D., Aguayo, N. R., Harrison, A., Najjar, M., Anguelov, M., Cox, A. O., Furdui, C. M., Watabe, K., Hollis, T., Thomas, A., Strowd, R., & Lo, H.-W. (2022). An FDA-approved antifungal, ketoconazole, and its novel derivative suppress tGLI1-mediated breast cancer brain metastasis by inhibiting the DNA-binding activity of brain metastasis-promoting transcription factor tGLI1. Cancers, 14(17), 4256. https://doi.org/10.3390/cancers14174256CrossRefPubMedPubMedCentral Doheny, D., Manore, S., Sirkisoon, S. R., Zhu, D., Aguayo, N. R., Harrison, A., Najjar, M., Anguelov, M., Cox, A. O., Furdui, C. M., Watabe, K., Hollis, T., Thomas, A., Strowd, R., & Lo, H.-W. (2022). An FDA-approved antifungal, ketoconazole, and its novel derivative suppress tGLI1-mediated breast cancer brain metastasis by inhibiting the DNA-binding activity of brain metastasis-promoting transcription factor tGLI1. Cancers, 14(17), 4256. https://​doi.​org/​10.​3390/​cancers14174256CrossRefPubMedPubMedCentral
190.
go back to reference West, D. C., Kocherginsky, M., Tonsing-Carter, E. Y., Dolcen, D. N., Hosfield, D. J., Lastra, R. R., Sinnwell, J. P., Thompson, K. J., Bowie, K. R., Harkless, R. V., Skor, M. N., Pierce, C. F., Styke, S. C., Kim, C. R., de Wet, L., Greene, G. L., Boughey, J. C., Goetz, M. P., Kalari, K. R., et al. (2018). Discovery of a glucocorticoid receptor (GR) activity signature using selective GR antagonism in ER-negative breast cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 24(14), 3433–3446. https://doi.org/10.1158/1078-0432.CCR-17-2793CrossRefPubMed West, D. C., Kocherginsky, M., Tonsing-Carter, E. Y., Dolcen, D. N., Hosfield, D. J., Lastra, R. R., Sinnwell, J. P., Thompson, K. J., Bowie, K. R., Harkless, R. V., Skor, M. N., Pierce, C. F., Styke, S. C., Kim, C. R., de Wet, L., Greene, G. L., Boughey, J. C., Goetz, M. P., Kalari, K. R., et al. (2018). Discovery of a glucocorticoid receptor (GR) activity signature using selective GR antagonism in ER-negative breast cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 24(14), 3433–3446. https://​doi.​org/​10.​1158/​1078-0432.​CCR-17-2793CrossRefPubMed
191.
go back to reference Munster, P. N., Greenstein, A. E., Fleming, G. F., Borazanci, E., Sharma, M. R., Custodio, J. M., Tudor, I. C., Pashova, H. I., Shepherd, S. P., Grauer, A., & Sachdev, J. C. (2022). Overcoming taxane resistance: Preclinical and phase 1 studies of relacorilant, a selective glucocorticoid receptor modulator, with nab-paclitaxel in solid tumors. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 28(15), 3214–3224. https://doi.org/10.1158/1078-0432.CCR-21-4363CrossRefPubMed Munster, P. N., Greenstein, A. E., Fleming, G. F., Borazanci, E., Sharma, M. R., Custodio, J. M., Tudor, I. C., Pashova, H. I., Shepherd, S. P., Grauer, A., & Sachdev, J. C. (2022). Overcoming taxane resistance: Preclinical and phase 1 studies of relacorilant, a selective glucocorticoid receptor modulator, with nab-paclitaxel in solid tumors. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 28(15), 3214–3224. https://​doi.​org/​10.​1158/​1078-0432.​CCR-21-4363CrossRefPubMed
Metadata
Title
Glucocorticoid receptor: a harmonizer of cellular plasticity in breast cancer—directs the road towards therapy resistance, metastatic progression and recurrence
Authors
Debanjan Thakur
Debomita Sengupta
Elizabeth Mahapatra
Salini Das
Ruma Sarkar
Sutapa Mukherjee
Publication date
03-01-2024
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 1/2024
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-023-10163-6

ASH 2024 Annual Meeting Coverage

inMIND supports tafasitamab addition in follicular lymphoma

Combining tafasitamab with lenalidomide and rituximab significantly improves progression-free survival for patients with relapsed or refractory follicular lymphoma.

Featuring the official presentation video

Read more
SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Watch now